PT  - JOURNAL ARTICLE
AU  - Laura Riva
AU  - Shuofeng Yuan
AU  - Xin Yin
AU  - Laura Martin-Sancho
AU  - Naoko Matsunaga
AU  - Sebastian Burgstaller-Muehlbacher
AU  - Lars Pache
AU  - Paul P. De Jesus
AU  - Mitchell V. Hull
AU  - Max Chang
AU  - Jasper Fuk-Woo Chan
AU  - Jianli Cao
AU  - Vincent Kwok-Man Poon
AU  - Kristina Herbert
AU  - Tu-Trinh Nguyen
AU  - Yuan Pu
AU  - Courtney Nguyen
AU  - Andrey Rubanov
AU  - Luis Martinez-Sobrido
AU  - Wen-Chun Liu
AU  - Lisa Miorin
AU  - Kris M. White
AU  - Jeffrey R. Johnson
AU  - Christopher Benner
AU  - Ren Sun
AU  - Peter G. Schultz
AU  - Andrew Su
AU  - Adolfo Garcia-Sastre
AU  - Arnab K. Chatterjee
AU  - Kwok-Yung Yuen
AU  - Sumit K. Chanda
TI  - A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals
AID  - 10.1101/2020.04.16.044016
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.04.16.044016
4099  - http://biorxiv.org/content/early/2020/04/17/2020.04.16.044016.short
4100  - http://biorxiv.org/content/early/2020/04/17/2020.04.16.044016.full
AB  - The emergence of novel SARS coronavirus 2 (SARS-CoV-2) in 2019 has triggered an ongoing global pandemic of severe pneumonia-like disease designated as coronavirus disease 2019 (COVID-19). To date, more than 2.1 million confirmed cases and 139,500 deaths have been reported worldwide, and there are currently no medical countermeasures available to prevent or treat the disease. As the development of a vaccine could require at least 12-18 months, and the typical timeline from hit finding to drug registration of an antiviral is >10 years, repositioning of known drugs can significantly accelerate the development and deployment of therapies for COVID-19. To identify therapeutics that can be repurposed as SARS-CoV-2 antivirals, we profiled a library of known drugs encompassing approximately 12,000 clinical-stage or FDA-approved small molecules. Here, we report the identification of 30 known drugs that inhibit viral replication. Of these, six were characterized for cellular dose-activity relationships, and showed effective concentrations likely to be commensurate with therapeutic doses in patients. These include the PIKfyve kinase inhibitor Apilimod, cysteine protease inhibitors MDL-28170, Z LVG CHN2, VBY-825, and ONO 5334, and the CCR1 antagonist MLN-3897. Since many of these molecules have advanced into the clinic, the known pharmacological and human safety profiles of these compounds will accelerate their preclinical and clinical evaluation for COVID-19 treatment.Competing Interest StatementThe authors have declared no competing interest.